21st Century Oncology has appointed radiation oncologist Dr. Steven Finkelstein as the company's chief science officer (CSO).
Finkelstein is an expert in prostate cancer and sarcoma and has a special interest in patient care and research for a variety of cancers, using radiation-driven personalized systemic therapy. He has held leadership roles at RSNA, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Radiation Therapy Oncology Group (RTOG).
Finkelstein also serves as the national director of the Translational Research Consortium, the research arm of 21st Century Oncology, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
